NCT00082485

Brief Summary

The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for phase_2

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 11, 2004

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 12, 2004

Completed
20 days until next milestone

Study Start

First participant enrolled

June 1, 2004

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2006

Completed
Last Updated

January 12, 2017

Status Verified

August 1, 2016

Enrollment Period

2.1 years

First QC Date

May 11, 2004

Last Update Submit

January 11, 2017

Conditions

Keywords

Cocaine Dependence

Outcome Measures

Primary Outcomes (1)

  • Effects of medication on cocaine craving

Study Arms (2)

1

ACTIVE COMPARATOR
Drug: Baclofen

2

PLACEBO COMPARATOR
Other: Placebo

Interventions

Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)

1
PlaceboOTHER

Placebo

2

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject must have DSM-IV diagnosis of cocaine dependence.
  • Subject must be seeking treatment for cocaine dependence.
  • Be be able to verbalize understanding of consent form, provide written consent and verbalize willingness to complete study procedures.

You may not qualify if:

  • Please contact site for more information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

San Francisco General Hosptial

San Francisco, California, 94110, United States

Location

Torrance Site

Torrance, California, 90502, United States

Location

Denver VA Medical Center

Denver, Colorado, 80220, United States

Location

VA Maryland Healthcare System

Baltimore, Maryland, 21201, United States

Location

U of Penn School of Medicine

Philadelphia, Pennsylvania, 19104 6178, United States

Location

South TX VA Health Care System

San Antonio, Texas, 78284 4404, United States

Location

Salt Lake City VA Medical Center

Salt Lake City, Utah, 84148, United States

Location

Institute of Resch & Educ Inova Fairfax Hospital

Falls Church, Virginia, 22042 3300, United States

Location

Related Publications (1)

  • Kahn R, Biswas K, Childress AR, Shoptaw S, Fudala PJ, Gorgon L, Montoya I, Collins J, McSherry F, Li SH, Chiang N, Alathari H, Watson D, Liberto J, Beresford T, Stock C, Wallace C, Gruber V, Elkashef A. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend. 2009 Jul 1;103(1-2):59-64. doi: 10.1016/j.drugalcdep.2009.03.011. Epub 2009 May 2.

MeSH Terms

Conditions

Cocaine-Related Disorders

Interventions

Baclofen

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic Chemicals

Study Officials

  • Liza Gorgon, M.A.

    VA Maryland Health Care System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NIH

Study Record Dates

First Submitted

May 11, 2004

First Posted

May 12, 2004

Study Start

June 1, 2004

Primary Completion

July 1, 2006

Last Updated

January 12, 2017

Record last verified: 2016-08

Locations